Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03657355 · ClinicalTrials.gov registry record · Phase 1

Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users

A Phase 1 study, sponsored by Idorsia Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
63
Enrollment target

NCT03657355 is a Phase 1 study that has completed, run by Idorsia Pharmaceuticals. The registered enrollment target is 63 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03657355, a Phase 1 study, has completed, sponsored by Idorsia Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
63 participants
Enrollment target

Study Summary

This placebo- and active controlled study will investigate the abuse potential of ACT-541468 in healthy recreational drug users

Interventions

  • DRUG Placebo
  • DRUG Suvorexant
  • DRUG Zolpidem
  • DRUG ACT-541468

Trial Details

FieldValue
Enrollment Target 63 participants
Start Date 2018-09-07
Est. Completion 2019-08-08
Phase Phase 1

Sponsor

Idorsia Pharmaceuticals

34 total trials

What the Registry Record Tells You About NCT03657355

The ClinicalTrials.gov registry entry for NCT03657355 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Idorsia Pharmaceuticals, which has 34 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.

NCT03657355 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03657355 about?

NCT03657355 is a clinical study titled "Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users". This placebo- and active controlled study will investigate the abuse potential of ACT-541468 in healthy recreational drug users

What is the current status of trial NCT03657355?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2018-09-07. Estimated completion is 2019-08-08.

What interventions are being tested in trial NCT03657355?

The interventions under investigation include: Placebo (DRUG), Suvorexant (DRUG), Zolpidem (DRUG), ACT-541468 (DRUG).

Who is sponsoring clinical trial NCT03657355?

This trial is sponsored by Idorsia Pharmaceuticals, which has 34 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.